TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00759551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
Study: NCT05610228

Intervention type: OTHER
Intervention: NO intervention
Description: No intervention
Study: NCT03733171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diluted epinephrine
Description: diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study: NCT03778073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab
Description: Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab + Ublituximab + Bendamustine combination
Description: Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab + Ublituximab + Bendamustine combination
Description: Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Study: NCT03165825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural Steroid Injection with Dexamethasone
Description: Transforaminal Epidural Steroid Injection with Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interlaminar Epidural Steroid Injection with Betamethasone
Description: Interlaminar Epidural Steroid Injection with Betamethasone
Study: NCT02207140

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HOWARU Restore
Study: NCT01730924

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary vein isolation using contact force sensing catheter
Study: NCT01943006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hirudoid cream 0.3 % Mucopolysaccharide polysulfate
Description: Hirudoid cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream without active substance
Study: NCT02010645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
Study: NCT03733171

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hemoclips
Description: diluted epinephrine was injected followed by application of hemoclips
Study: NCT05452395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-acute care
Description: A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification.
Study: NCT02207140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HOWARU Restore
Study: NCT02173990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept-FOLFIRI
Description: Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²
Study: NCT03560154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
Study: NCT01722552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Study: NCT03984916

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin Pharma
Description: Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin Pharma_M
Description: Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiose
Description: Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
Study: NCT01728454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching capsules, orally, once daily for 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone acetate
Description: Telapristone acetate capsules, orally once daily for 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone acetate
Description: Telapristone acetate capsules, orally once daily for 18 weeks.
Study: NCT02763605

Intervention type: OTHER
Intervention: no intervention
Study: NCT01278966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Modified Atkins Diet
Description: The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
Study: NCT01882036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass w/ matched hypocaloric diet
Description: Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: Hypocaloric liquid diet for 10 days
Study: NCT02155660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm A
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm B
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm C
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study: NCT04384952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-administered reading therapy.
Description: Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyslexic's Holiday Workbook
Description: Use of a special Dyslexic's holiday book, no parent-guided training.
Study: NCT00758394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush two times a day for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush two times daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan/Fluoride
Description: Brush twice daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triclosan/Fluoride
Description: Brush twice daily for 4 days
Study: NCT00396266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT03862729

Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.

Intervention type: PROCEDURE
Intervention: conventional treatment
Description: Conventional treatment includes medical treatment and conventional craniotomy.
Study: NCT03776331

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: Measurement of the change in the vasodilatative reserve of the brachial artery

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated dilation
Description: Measurement of the change in the vasodilatative reserve of the brachial artery
Study: NCT03820804

Intervention type: OTHER
Intervention: Diet
Description: A specific dietary treatment for patients with Phenylketonuria.

Intervention type: DRUG
Intervention: Sapropterin
Description: A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
Study: NCT01297621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduction mammaplasty
Description: conventional reduction mammaplasty

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: follow up, questionnaire responses
Study: NCT02781662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Home-Visit
Study: NCT03506464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: The same described in the arm description
Study: NCT04417816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training intervention with ultrasound induced adipose tissue cavitation
Description: Exercise training intervention with ultrasound induced adipose tissue cavitation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise training intervention without ultrasound induced adipose tissue cavitation
Description: Exercise training intervention with ultrasound induced adipose tissue cavitation
Study: NCT03638388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling (DN)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with intramuscular electrical stimulation (DNES)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
Study: NCT00465894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Tolterodine LA
Description: Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra Vaginal Estradiol Cream
Description: 17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
Study: NCT03725709

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
Study: NCT02438111

Intervention type: GENETIC
Intervention: metagenome
Description: metagenome

Intervention type: GENETIC
Intervention: metagenome
Description: metagenome
Study: NCT04144257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]Methylreboxetine
Description: PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
Study: NCT01231620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match zanamivir
Description: Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir will be provided as over-encapsulated 75 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match oseltamivir
Description: Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match oseltamivir
Description: Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
Study: NCT02833142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 (opicinumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 (opicinumab)
Study: NCT01941160

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil® STRONG
Description: Lacidofil® STRONG capsule twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule twice daily
Study: NCT05737927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 8 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose 12 g coated beads (47% w/w)
Description: After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study: NCT02271945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 12 mg/kg
Description: Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551 12 mg/kg
Description: Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 2.5 mg/kg
Description: Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 10 mg/kg
Description: Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
Study: NCT01940536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: antifibrinolytic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00256516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eco-Atkins diet (high vegetable protein and vegetable fat)
Study: NCT01184105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B
Description: A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B
Description: A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Study: NCT02131402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon D
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A
Description: Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
Study: NCT01536379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study: NCT00006079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
Study: NCT02836899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Study: NCT04189601

Intervention type: DIAGNOSTIC_TEST
Intervention: Complement measurements
Description: Blood and urine tests to assess the complement activation state

Intervention type: DIAGNOSTIC_TEST
Intervention: Complement measurements
Description: Blood and urine tests to assess the complement activation state
Study: NCT02430480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 10.8mg administered subcutaneously every 12 weeks (2 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg orally, daily for 24 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: Multiparametric MRI - One at baseline and after 6 months of treatment